Lycecort Tablet contains Deflazacort 6 mg, a corticosteroid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory and autoimmune conditions, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, polymyositis, and certain allergic disorders. Deflazacort acts by modulating the immune response and reducing inflammation through inhibition of multiple inflammatory cytokines and mediators. Compared to other corticosteroids, Deflazacort is associated with a lower incidence of adverse metabolic effects, making it a preferred option in long-term therapy. The recommended dosage and duration of treatment with Lycecort Tablet should be individualized based on the severity of the condition and patient response, with gradual tapering advised to prevent adrenal insufficiency upon discontinuation. Common side effects may include gastrointestinal discomfort, increased susceptibility to infections, hyperglycemia, and mood alterations. Caution is warranted in patients with diabetes, hypertension, osteoporosis, or peptic ulcer disease. Lycecort Tablet should be used under strict medical supervision, with regular monitoring of clinical and laboratory parameters to optimize therapeutic outcomes and minimize potential risks. It is contraindicated in patients with systemic fungal infections and known hypersensitivity to Deflazacort or other corticosteroids.